» Articles » PMID: 20539838

Optimal Use of Beta-blockers in High-risk Hypertension: a Guide to Dosing Equivalence

Overview
Publisher Dove Medical Press
Date 2010 Jun 12
PMID 20539838
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Hypertension is the number one diagnosis made by primary care physicians, placing them in a unique position to prescribe the antihypertensive agent best suited to the individual patient. In individuals with diabetes mellitus, blood pressure (BP) levels>130/80 mmHg confer an even higher risk for cardiovascular and renal disease, and these patients will benefit from aggressive antihypertensive treatment using a combination of agents. beta-blockers are playing an increasingly important role in the management of hypertension in high-risk patients. beta-blockers are a heterogeneous class of agents, and this review presents the differences between beta-blockers and provides evidence-based protocols to assist in understanding dose equivalence in the selection of an optimal regimen in patients with complex needs. The clinical benefits provided by beta-blockers are only effective if patients adhere to medication treatment long term. beta-blockers with proven efficacy, once-daily dosing, and lower side effect profiles may become instrumental in the treatment of hypertensive diabetic and nondiabetic patients.

Citing Articles

Beta-Blocker Use during Pregnancy Correlates with Less Aortic Root Dilatation in Patients with Marfan's Syndrome.

Roberts E, Pistner A, Osobamiro O, Banning S, Shalhub S, Albright C Aorta (Stamford). 2023; 11(2):63-70.

PMID: 37055016 PMC: 10232026. DOI: 10.1055/a-2072-0469.


Migraine-preventive prescription patterns by physician specialty in ambulatory care settings in the United States.

Takaki H, Onozuka D, Hagihara A Prev Med Rep. 2018; 9:62-67.

PMID: 29340272 PMC: 5766757. DOI: 10.1016/j.pmedr.2017.12.009.


Antihypertensive drug class and adherence: an electronic monitoring study.

Moise N, Schwartz J, Bring R, Shimbo D, Kronish I Am J Hypertens. 2014; 28(6):717-21.

PMID: 25344354 PMC: 4447817. DOI: 10.1093/ajh/hpu199.

References
1.
Tse W, Kendall M . Is there a role for beta-blockers in hypertensive diabetic patients?. Diabet Med. 1994; 11(2):137-44. DOI: 10.1111/j.1464-5491.1994.tb02009.x. View

2.
Cockcroft J . A review of the safety and efficacy of nebivolol in the mildly hypertensive patient. Vasc Health Risk Manag. 2008; 3(6):909-17. PMC: 2350132. View

3.
. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160):713-20. PMC: 28660. View

4.
Sarafidis P, Bogojevic Z, Basta E, Kirstner E, Bakris G . Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich). 2008; 10(2):112-8. PMC: 8109968. DOI: 10.1111/j.1751-7176.2008.08021.x. View

5.
Cooper-DeHoff R, Handberg E, Cohen J, Kowey P, Messerli F, Mancia G . Characteristics of contemporary patients with hypertension and coronary artery disease. Clin Cardiol. 2004; 27(10):571-6. PMC: 6654359. DOI: 10.1002/clc.4960271010. View